S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:REPL

Replimune Group Stock Forecast, Price & News

$29.00
-1.99 (-6.42%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.43
$31.19
50-Day Range
$28.95
$34.25
52-Week Range
$27.66
$54.79
Volume
181,299 shs
Average Volume
309,515 shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
30 days | 90 days | 365 days | Advanced Chart
Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.


Replimune Group logo

About Replimune Group

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Headlines

Replimune Group (NASDAQ:REPL) Trading 6.9% Higher
November 19, 2021 |  americanbankingnews.com
Replimune Group's (REPL) "Buy" Rating Reaffirmed at HC Wainwright
November 15, 2021 |  americanbankingnews.com
Notable Replimune Group Insider Makes $408K Sale
September 28, 2021 |  benzinga.com
Notable Replimune Group Insider Makes $None Sale
September 28, 2021 |  benzinga.com
Replimune Group Inc (REPL) COO Colin Love Sold $936,900 of Shares
September 21, 2021 |  ca.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$9.75 per share

Profitability

Net Income
$-80.87 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
27,995,000
Market Cap
$1.36 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/27/2021
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

190th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

29th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Replimune Group (NASDAQ:REPL) Frequently Asked Questions

Is Replimune Group a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group
or view top-rated stocks.

How has Replimune Group's stock price been impacted by COVID-19 (Coronavirus)?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have increased by 143.1% and is now trading at $29.00.
View which stocks have been most impacted by COVID-19
.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Replimune Group
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05.
View Replimune Group's earnings history
.

What price target have analysts set for REPL?

4 Wall Street analysts have issued 1 year price targets for Replimune Group's stock. Their forecasts range from $49.00 to $60.00. On average, they expect Replimune Group's share price to reach $55.00 in the next year. This suggests a possible upside of 89.7% from the stock's current price.
View analysts' price targets for Replimune Group
or view top-rated stocks among Wall Street analysts.

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.47%), Ensign Peak Advisors Inc (2.75%), Emerald Mutual Fund Advisers Trust (2.17%), BVF Inc. IL (1.98%), Emerald Advisers LLC (1.97%) and Victory Capital Management Inc. (1.78%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group
.

Which major investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, Invesco Ltd., Victory Capital Management Inc., Citigroup Inc., Two Sigma Investments LP, Two Sigma Advisers LP, Morgan Stanley, and Millennium Management LLC. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, and Robert Coffin.
View insider buying and selling activity for Replimune Group
or view top insider-selling stocks.

Which major investors are buying Replimune Group stock?

REPL stock was acquired by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Dimensional Fund Advisors LP, BlackRock Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC, Goldman Sachs Group Inc., and UBS Group AG.
View insider buying and selling activity for Replimune Group
or or view top insider-buying stocks.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $29.00.

How much money does Replimune Group make?

Replimune Group has a market capitalization of $1.36 billion. The company earns $-80.87 million in net income (profit) each year or ($1.94) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 152 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

Where are Replimune Group's headquarters?

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at (781) 222-9600 or via email at [email protected].


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.